Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns
Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second quarter of 2023
https://finance.yahoo.com/news/mediwound-announces-fda-approval-nexobrid-184600392.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.